| 44.29 1.84 (4.33%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.47 |
1-year : | 61.29 |
| Resists | First : | 44.93 |
Second : | 52.47 |
| Pivot price | 40.3 |
|||
| Supports | First : | 38.21 |
Second : | 34.06 |
| MAs | MA(5) : | 43.13 |
MA(20) : | 39.73 |
| MA(100) : | 33.82 |
MA(250) : | 31 |
|
| MACD | MACD : | 2.2 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 81.9 |
D(3) : | 83  |
| RSI | RSI(14): 74.2 |
|||
| 52-week | High : | 44.93 | Low : | 25.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALKS ] has closed below upper band by 13.2%. Bollinger Bands are 90% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.95 - 45.17 | 45.17 - 45.4 |
| Low: | 42.52 - 42.74 | 42.74 - 42.97 |
| Close: | 43.92 - 44.28 | 44.28 - 44.65 |
Alkermes plc is an Irish-headquartered biopharmaceutical firm, established in 1987, focused on the discovery, development, and commercialization of innovative pharmaceutical treatments. These efforts are directed at fulfilling critical unmet medical needs for patients across a range of therapeutic areas, both domestically and internationally. Its current portfolio of marketed products features ARISTADA for schizophrenia; VIVITROL, targeting alcohol dependence and preventing opioid dependence; and several medications for schizophrenia and bipolar I disorder, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA. Furthermore, VUMERITY is available for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting, and active secondary progressive diseases. The company is also actively developing new drug candidates, such as LYBALVI, an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein designed to amplify tumor-killing immune cells while bypassing the activation of immunosuppressive cells. Alkermes maintains key strategic collaboration agreements, primarily with various entities under the Janssen Pharmaceutica umbrella.
Tue, 09 Jun 2026
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tel - GuruFocus
Tue, 09 Jun 2026
Alkermes Jumps 5.6% After RBC Capital Maintains Outperform - AlphaStreet
Mon, 08 Jun 2026
Alkermes Plc (ALKS) Stock Analysis: Strong Buy Ratings And Promising Growth Potential - DirectorsTalk Interviews
Sun, 07 Jun 2026
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors? - Yahoo Finance
Thu, 04 Jun 2026
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Thu, 04 Jun 2026
[144] Alkermes plc. SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 167 (M) |
| Shares Float | 154 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 110.2 (%) |
| Shares Short | 18,280 (K) |
| Shares Short P.Month | 19,680 (K) |
| EPS | 0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.52 |
| Profit Margin | 9.7 % |
| Operating Margin | -0.2 % |
| Return on Assets (ttm) | 4.7 % |
| Return on Equity (ttm) | 9.3 % |
| Qtrly Rev. Growth | 28.2 % |
| Gross Profit (p.s.) | 8.21 |
| Sales Per Share | 9.35 |
| EBITDA (p.s.) | 1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 256 (M) |
| Levered Free Cash Flow | 141 (M) |
| PE Ratio | 49.21 |
| PEG Ratio | 1.9 |
| Price to Book value | 4.21 |
| Price to Sales | 4.73 |
| Price to Cash Flow | 28.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|